Skip to main content
Equibles
IDYA logo

IDYA · IDEAYA Biosciences, Inc.

Track IDYA — free

Use IDYA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IDYA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$39.67 +0.56 (+1.43%) At close · Aug 21
Market Cap
$3.89B
Shares
96.49M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$39.67 Open$39.34 Day$39.31–40.56 52W close$23.39–40.51 Avg vol 30d756K Short int10.1M · 10.5% float · 13.2d Short vol52% Last earningsNov 4, 2024 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg +10%
above
RSI (14) 69
neutral
MACD trend Positive
52-week position 95%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +20%
trailing
YTD return +15%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $36 › 200d $33 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +65 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.48% of float · ▲ +5.6% MoM · 13.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
284 holders — near 3-yr high, broad support
Squeeze score 82
high risk · 0–100
Fundamentals
Strong
Revenue growth +3024%
Y/Y
EPS growth +62%
Y/Y
Free cash flow $-73.5M
Balance sheet $112.8M
net cash
Quant / Vol
risk profile
High
Volatility 48%
annualized · 1-yr
Max drawdown −27%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
69 Neutral
MACD trend
Positive Bullish
52-week position
95% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $36 › 200d $33 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +65 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.48% of float · ▲ +5.6% MoM · 13.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
284 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $23 Now $40 · 95% Range high $41
vs 200-day avg +19% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and marketable securities 1.24B Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IDYA
IDEAYA Biosciences, Inc.
this stock
$3.89B +14.8% +3024.4% — 10.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
284
% held
106.5%
Net QoQ
+5.8M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
243
View
Short & Settlement
Short Interest Rising
Shares short
10.1M
Days to cover
13.2d
Change
+539.6K sh
View
Short Volume
Short vol %
52%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
6
Value
$214
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
34.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$218.7M
Net income (FY)
$-113.7M
EPS diluted
$-1.28
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
18
View
Proposed Sales
Value
$3.0M
Shares
75.0K
Filed
Aug 26, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IDYA +9.3% +12.1% +20.1% +11.8% +14.8%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +10.7% +8.4% +8.5% +9.3% +2.5%
Key facts CIK 1676725 CUSIP 45166A102 13F (30d) 264 filings 259 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)